An old herbal medicine with a potentially new therapeutic application in inflammatory bowel disease

International Journal of Clinical and Experimental Medicine

Volumn 4, Issue 4, 2011, Pages 309-319

  Li, Richard ^a,b   Alex, Philip ^a   Ye, Mei ^a,c   Zhang, Ting ^a   Liu, Ling ^c   Li, Xuhang ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c WUHAN UNIVERSITY   (China)

Author keywords

Complementary and alternative medicine (CAM); Crohn's disease; Cytokines; DSS colitis; Herbal medicine; IBD; Immunesuppression; TNBS colitis; Wound healing; Yunnan baoyao (YNBY)

Indexed keywords

AMPICILLIN; GAMMA INTERFERON; HERBACEOUS AGENT; INTERLEUKIN 12P40; INTERLEUKIN 17; MERCAPTOPURINE; MESALAZINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; YUNNAN BAIYAO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE; BACTERIAL GROWTH; CELL SPREADING; CELL STRAIN CACO 2; CHINESE MEDICINE; COLITIS; COLON MUCOSA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; ESCHERICHIA COLI; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; MALE; MOUSE; NONHUMAN; T LYMPHOCYTE; TOXICITY TESTING; WOUND HEALING;

EID: 82955168433     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427-434.
2. Strober W, Fuss I and Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007; 117: 514-521.
3. Packey CD, Sartor RB. Interplay of commensal and pathogenic bacteria, genetic mutations, and immunoregulatory defects in the pathogenesis of inflammatory bowel diseases. J Intern Med 2008; 263: 597-606.
4. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 390-407.
5. Kappelman MD, Rifas Shiman SL, Kleinman K, Ollendorf D, Bousvaros A, Grand RJ and Finkelstein JA. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007; 5: 1424-1429.
6. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369: 1641-1657.
7. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, Mitton S, Orchard T, Rutter M, Younge L, Lees C, Ho GT, Satsangi J and Bloom S. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60: 571-607.
8. Plevy SE, Targan SR. Future therapeutic approaches for inflammatory bowel diseases. Gastroenterology 2011; 140: 1838-1846.
9. Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW, Johanns J, Lang Y and Sandborn WJ. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009; 30: 210-226.
10. Siegel CA, Hur C, Korzenik JR, Gazelle GS and Sands BE. Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1017-1024.
11. Blonski W, Lichtenstein GR. Safety of biologic therapy. Inflamm Bowel Dis 2007; 13: 769-796.
12. Sands BE. Therapy of inflammatory bowel disease. Gastroenterology 2000; 118: S68-S82.
13. Sands BE. New therapies for the treatment of inflammatory bowel disease. Surg Clin North Am 2006; 86: 1045-1064.
14. Fraser AG, Orchard TR and Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 485-489.
15. Fraser AG, Orchard TR, Robinson EM and Jewell DP. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther 2002; 16: 1225-1232.
16. Caviglia R, Boskoski I and Cicala M. Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opin Drug Saf 2008; 7: 617-632.
17. Rutgeerts P, Van AG and Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126: 1593-1610.
18. Wieland LS, Manheimer E and Berman BM. Development and classification of an operational definition of complementary and alternative medicine for the Cochrane collaboration. Altern Ther Health Med 2011; 17: 50-59.
19. Ruggie M. Mainstreaming complementary therapies: new directions in health care. Health Aff (Millwood) 2005; 24: 980-990.
20. Herman PM, Craig BM and Caspi O. Is complementary and alternative medicine (CAM) costeffective? A systematic review. BMC Complement Altern Med 2005; 5: 11.
21. MacLennan AH, Wilson DH and Taylor AW. The escalating cost and prevalence of alternative medicine. Prev Med 2002; 35: 166-173.
22. Lu AP, Jia HW, Xiao C and Lu QP. Theory of traditional Chinese medicine and therapeutic method of diseases. World J Gastroenterol 2004; 10: 1854-1856.
23. Yu F, Takahashi T, Moriya J, Kawaura K, Yamakawa J, Kusaka K, Itoh T, Morimoto S, Yamaguchi N and Kanda T. Traditional Chinese medicine and Kampo: a review from the distant past for the future. J Int Med Res 2006; 34: 231-239.
24. Li WF, Jiang JG and Chen J. Chinese medicine and its modernization demands. Arch Med Res 2008; 39: 246-251.
25. Debas HT, Laxminarayan R and Straus SE. Complementary and Alternative Medicine. 2006.
26. Khanna D, Sethi G, Ahn KS, Pandey MK, Kunnumakkara AB, Sung B, Aggarwal A and Aggarwal BB. Natural products as a gold mine for arthritis treatment. Curr Opin Pharmacol 2007; 7: 344-351.
27. Carroll RJ. Complementry and Alternative Medicine- History, Definitions, and What Is It Today? 2007; 7-43.
28. Power M, Hopayian K. Exposing the evidence gap for complementary and alternative medicine to be integrated into science-based medicine. J R Soc Med 2011; 104: 155-161.
29. Long AF. Outcome measurement in complementary and alternative medicine: unpicking the effects. J Altern Complement Med 2002; 8: 777-786.
30. Joos S. Review on efficacy and health services research studies of complementary and alternative medicine in inflammatory bowel disease. Chin J Integr Med 2011; 17: 403-409.
31. Robinson NG. Yunnan Paiyao. http://CsuvetsColostateEdu/Pain/Articlespdf/YunnanPaiyao111206Pdf 2007; 1-4.
32. Bergner P. Panax notoginseng Yunnan bai yao: A must for the first aid kit. Medical Herbalism 1994; 6: 12.
33. Fan C, Song J and White CM. A comparision of the hemostatic effects of notoginseng and yun nan bai yao to placebo control. J Herb Pharmacother 2005; 5: 1-5.
34. Tang ZL, Wang X, Yi B, Li ZL, Liang C and Wang XX. Effects of the preoperative administration of Yunnan Baiyao capsules on intraoperative blood loss in bimaxillary orthognathic surgery: a prospective, randomized, double-blind, placebo -controlled study. Int J Oral Maxillofac Surg 2009; 38: 261-266.
35. Sarker R, Valkhoff VE, Zachos NC, Lin R, Cha B, Chen TE, Guggino S, Zizak M, de JH, Hogema B and Donowitz M. NHERF1 and NHERF2 are necessary for multiple but usually separate aspects of basal and acute regulation of NHE3 activity. Am J Physiol Cell Physiol 2011; 300: C771-C782.
36. Alex P, Zachos NC, Nguyen T, Gonzales L, Chen TE, Conklin LS, Centola M and Li X. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis 2009; 15: 341-352.
37. Alex P, Ye M, Zachos NZ, Sipes J, Nguyen T, Suhodrev M, Gonzales L, Arora Z, Zhang T, Centola M, Guggino SE and Li X. Clc-5 Knockout Mice Exhibit Novel Immunomodulatory Effects And Are More Susceptible to Dextran Sulphate Sodium Induced Colitis. J Immunol 2010; 184: 3988-3996.
38. Seltana A, Basora N and Beaulieu JF. Intestinal epithelial wound healing assay in an epithelialmesenchymal co-culture system. Wound Repair Regen 2010; 18: 114-122.
39. Xavier R, Podolsky DK. Commensal flora: wolf in sheep's clothing. Gastroenterology 2005; 128: 1122-1126.
40. Chichlowski M, Hale LP. Bacterial-mucosal interactions in inflammatory bowel disease: an alliance gone bad. Am J Physiol Gastrointest Liver Physiol 2008; 295: G1139-G1149.
41. Li X, Conklin L and Alex P. New serological biomarkers of inflammatory bowel disease. World J Gastroenterol 2008; 14: 5115-5124.
42. Sanchez Munoz F, Dominguez Lopez A and Yamamoto-Furusho JK. Role of cytokines in inflammatory bowel disease. World J Gastroenterol 2008; 14: 4280-4288.
43. Flynn A, Kane S. Mucosal healing in Crohn's disease and ulcerative colitis: what does it tell us? Curr Opin Gastroenterol 2011; 27: 342-345.
44. Baert F, Moortgat L, Van AG, Caenepeel P, Vergauwe P, de VM, Stokkers P, Hommes D, Rutgeerts P, Vermeire S and D'Haens G. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010; 138: 463-468.
45. Pineton de CG, Peyrin Biroulet L, Lemann M and Colombel JF. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010; 7: 15-29.
46. Lenaghan SC, Xia L and Zhang M. Identification of nanofibers in the Chinese herbal medicine: Yunnan Baiyao. J Biomed Nanotechnol 2009; 5: 472-476.
47. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011; 140: 1756-1767.
48. Melmed GY, Targan SR. Future biologic targets for IBD: potentials and pitfalls. Nat Rev Gastroenterol Hepatol 2010; 7: 110-117.
49. De ND, Sarra M, Cupi ML, Pallone F and Mon teleone G. Targeting IL-23 and Th17-cytokines in inflammatory bowel diseases. Curr Pharm Des 2010; 16: 3656-3660.
50. Sandborn WJ. Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology 2008; 135: 1442-1447.
51. Benson JM, Sachs CW, Treacy G, Zhou H, Pendley CE, Brodmerkel CM, Shankar G and Mascelli MA. Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab. Nat Biotechnol 2011; 29: 615-624.